Publicaciones (15) Publicaciones de MARINA MENDIBURU-ELIÇABE GARGANTA

2024

  1. CRISPR/Cas9 screenings unearth protein arginine methyltransferase 7 as a novel essential gene in prostate cancer metastasis

    Cancer Letters, Vol. 588

  2. POTEE promotes breast cancer cell malignancy by inducing invadopodia formation through the activation of SUMOylated Rac1

    Molecular Oncology, Vol. 18, Núm. 3, pp. 620-640

2023

  1. Intermediate Molecular Phenotypes to Identify Genetic Markers of Anthracycline-Induced Cardiotoxicity Risk

    Cells, Vol. 12, Núm. 15

  2. TMeB score may improve risk stratification of high-risk cutaneous squamous cell carcinoma and guide management of patients: A pilot study

    Journal of the European Academy of Dermatology and Venereology

2022

  1. Evolutionary Origins of Metabolic Reprogramming in Cancer

    International journal of molecular sciences, Vol. 23, Núm. 20

  2. From Mouse to Human: Cellular Morphometric Subtype Learned From Mouse Mammary Tumors Provides Prognostic Value in Human Breast Cancer

    Frontiers in Oncology, Vol. 11

  3. Pathophysiological Integration of Metabolic Reprogramming in Breast Cancer

    Cancers, Vol. 14, Núm. 2

2021

  1. The pseudokinase TRIB3 negatively regulates the HER2 receptor pathway and is a biomarker of good prognosis in luminal breast cancer

    Cancers, Vol. 13, Núm. 21

2020

  1. Midkine signaling maintains the self-renewal and tumorigenic capacity of glioma initiating cells

    Theranostics, Vol. 10, Núm. 11, pp. 5120-5136

  2. Stromal SNAI2 is required for ERBB2 breast cancer progression

    Cancer Research, Vol. 80, Núm. 23, pp. 5216-5230

2019

  1. Circular troughs in tessera terrain on Venus: Morphometry, structural analysis and possible formation model

    Planetary and Space Science, Vol. 178

2015

  1. Combination therapy of intraperitoneal rapamycin and convection-enhanced delivery of nanoliposomal CPT-11 in rodent orthotopic brain tumor Xenografts

    Current Cancer Drug Targets, Vol. 15, Núm. 4, pp. 352-362

2014

  1. Efficacy of rapamycin against glioblastoma cancer stem cells

    Clinical and Translational Oncology, Vol. 16, Núm. 5, pp. 495-502

2012

  1. Systemic rapamycin alone may not be a treatment option for malignant glioma: Evidence from an in vivo study

    Journal of Neuro-Oncology, Vol. 108, Núm. 1, pp. 53-58

2011

  1. An off-target nucleostemin RNAi inhibits growth in human glioblastoma-derived cancer stem cells

    PLoS ONE, Vol. 6, Núm. 12